Disruptive Technology Channel Eye DNA Synthesis Advances in Active Biotech ETF ARKG By Nick Peters-GoldenFebruary 1, 2023
Disruptive Technology Channel EXAS Nears Key Buy Signal in Active Biotech ETF ARKG By Nick Peters-GoldenJanuary 11, 2023
Thematic Investing Channel Capture the Growth Potential in China’s Biotech Sector With This ETF By Ben HernandezDecember 27, 2022
Disruptive Technology Channel Biotech Earnings, Market Leap Boost ARKG Potential By Nick Peters-GoldenNovember 11, 2022
Leveraged & Inverse Channel Biotech Bounces in August as M&A Activity Increases By Ben HernandezAugust 22, 2022
Thematic Investing Channel Capitalize on Biotech Growth in China With This ETF By Ben HernandezJuly 21, 2022
Leveraged & Inverse Channel Biotech Belonged to the Bears in Second Half of 2021 By Ben HernandezDecember 25, 2021
Leveraged & Inverse Channel Omicron Variant Is Boosting This Leveraged Biotech ETF By Ben HernandezDecember 15, 2021
Nasdaq Investment Intelligence Channel How to Invest in Biotech in 2022 By Karrie GordonDecember 15, 2021
Leveraged & Inverse Channel This Bearish Biotech ETF Is up 16% in the Past Month By Ben HernandezOctober 12, 2021
Thematic Investing Channel The CHB ETF: China’s Burgeoning Biotech Sector By Ben HernandezMay 7, 2021
Leveraged & Inverse Channel Biotech Rose with the Virus. Now It’s Falling Behind By Ben HernandezMarch 19, 2021
Beyond Basic Beta Channel IPOs Are Back. Get In On the Action with the BBH ETF By Ben HernandezFebruary 9, 2021
Leveraged & Inverse Channel Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs By Ben HernandezNovember 24, 2020
Beyond Basic Beta Channel Bullish on Biotech? The BBH ETF is Not Just a 2020 Play By Ben HernandezNovember 18, 2020
Beyond Basic Beta Channel Can’t Get Enough Biotech Exposure in Your Portfolio? By Ben HernandezOctober 29, 2020
